{ "report_id": "security_ntra", "report_type": "security_detail", "site_path": "securities/ntra/index.html", "title": "NTRA - Natera Operating Console", "ticker": "NTRA", "company": "Natera", "as_of": "2026-06-07T23:02:00.712546Z", "generated_at": "2026-06-24T04:52:11Z", "summary": "Static report-layer operating console projection of the canonical NTRA knowledge lane with a live selected-security chart module, proof window, KPI strip, exposure cards, guidance tests, trigger board, risk punch cards, diagnostics, source links, and dated street-view routes.", "boundaries": { "canonical_research_storage": "../../../knowledge/wiki/lanes/security/ntra.md", "report_role": "Readable projection, routing surface, and chart host only.", "discovery_policy": "Read local report API outputs only; do not mutate discovery from this page.", "chart_rules_policy": "Persisted chart overlays and plan rules remain in assets/chart-level-rules.js.", "portfolio_policy": "No portfolio action, sizing, buy/sell recommendation, or trade instruction is stored in this report." }, "freshness": { "knowledge_lane_reviewed_as_of": "2026-06-07T23:02:00.712546Z", "latest_profile_run_id": "security_backlog_100_20260607_refresh_20260607", "latest_research_run_id": "security_backlog_100_20260607_refresh_20260607", "market_data_in_lane_as_of": "2026-06-05", "web_links_checked_as_of": "2026-06-24", "chart_data_as_of": "latest available from /api/securities/NTRA/chart", "latest_source_diagnostics": { "has_stale_sources": false, "missing_required_source_ids": [ "earnings_call_transcripts_last_4", "latest_investor_presentation_or_q1_2026_slide_deck", "rating_agency_reports_if_any", "local_13f_holdings_for_ntra" ], "source_count": 13, "diagnostic_gaps": [ "Last four full earnings-call transcripts were not parsed; guidance history relies on earnings releases and filings rather than Q&A tone and dropped language.", "Latest investor presentation or Q1 2026 slide deck was identified but not fully parsed.", "Local 13F holdings coverage for NTRA is empty, so institutional flow and passive ownership context are incomplete.", "Product-level revenue, gross margin, and profit by oncology, women's health, and organ health are not disclosed through segment reporting." ] }, "limitations": [ "The dashboard summarizes the filed NTRA lane rather than refreshing canonical research.", "Operating evidence remains anchored to the latest paired NTRA source projections generated 2026-06-07.", "Market valuation, short-interest, insider-flow, beta, and price-action values are sourced from the latest lane's June 5, 2026 market-data snapshot and local filing tables.", "Live price and market-cap values resolve only when the local report API is running.", "Public filings do not isolate oncology, women's health, organ health, or Foresight standalone economics.", "Web-derived analyst items are aggregator-sourced and may differ by provider methodology, publication date, and real-time refresh cadence.", "The page does not store chart overlay definitions, page-specific trigger prices, or portfolio instructions." ] }, "source_trail": { "canonical_knowledge_lane": "../../../knowledge/wiki/lanes/security/ntra.md", "profile_source_id": "security_profile__ntra__security_backlog_100_20260607_refresh_20260607", "research_source_id": "security_research__ntra__security_backlog_100_20260607_refresh_20260607", "latest_profile_output": "../../../knowledge/raw/sources/security_profile__ntra__security_backlog_100_20260607_refresh_20260607/output.md", "latest_profile_output_json": "../../../knowledge/raw/sources/security_profile__ntra__security_backlog_100_20260607_refresh_20260607/output.json", "latest_profile_manifest": "../../../knowledge/raw/sources/security_profile__ntra__security_backlog_100_20260607_refresh_20260607/source.json", "latest_profile_output_hash": "sha256:8afba9970876f59522763e2f017d12d06595d9f80d9b1041f741c7fed15f5386", "latest_research_output": "../../../knowledge/raw/sources/security_research__ntra__security_backlog_100_20260607_refresh_20260607/output.md", "latest_research_output_json": "../../../knowledge/raw/sources/security_research__ntra__security_backlog_100_20260607_refresh_20260607/output.json", "latest_research_manifest": "../../../knowledge/raw/sources/security_research__ntra__security_backlog_100_20260607_refresh_20260607/source.json", "latest_research_output_hash": "sha256:45972e75d507d13c6244910159f50377b7a40e2f4c5445a9ba445d9f61bb0ad7", "profile_generated_at_utc": "2026-06-07T23:02:00Z", "profile_as_of_utc": "2026-06-07T23:02:00.712546Z", "profile_exported_at_utc": "2026-06-07T23:21:37Z", "research_generated_at_utc": "2026-06-07T23:04:00Z", "research_exported_at_utc": "2026-06-07T23:21:37Z", "profile_used_reused_inputs": true, "research_used_reused_inputs": false, "upstream_hashes": { "security_research": "45972e75d507d13c6244910159f50377b7a40e2f4c5445a9ba445d9f61bb0ad7", "sector_context_health_care": "afb9570210d03c2f37373457c217090a96d68a10bece240743c5b5bce91ab4be" }, "source_claims_projected": [ "C001", "C002", "C003", "C004", "C005", "C006", "C007", "C008", "C009", "C010" ], "source_evidence_ids_projected": [ "E001", "E002", "E003", "E004", "E005", "E006", "E007", "E008", "E009", "E010", "E011", "E012", "E013", "E014", "E015", "E016", "E017", "E018", "E019", "E020", "E021", "E022", "E023", "E024", "E025", "E026" ], "profile_object_ids_projected": [ "NTRA_PATH_001", "NTRA_PATH_002", "NTRA_PATH_003", "NTRA_PATH_004", "NTRA_FCST_001", "NTRA_FCST_002", "NTRA_FCST_003", "NTRA_FCST_004", "NTRA_KPI_001", "NTRA_KPI_002", "NTRA_KPI_003", "NTRA_KPI_004", "NTRA_KPI_005", "NTRA_KPI_006", "NTRA_TRIG_001", "NTRA_TRIG_002", "NTRA_TRIG_003", "NTRA_TRIG_004", "NTRA_TRIG_005", "NTRA_TRIG_006", "NTRA_TRIG_007", "NTRA_RISK_001", "NTRA_RISK_002", "NTRA_RISK_003", "NTRA_RISK_004", "NTRA_KU_001", "NTRA_KU_002", "NTRA_KU_003", "NTRA_KU_004", "NTRA_KU_005", "NTRA_BASE", "NTRA_UP", "NTRA_DOWN" ], "local_chart_endpoints": [ "/api/securities/NTRA/chart?frequency=daily&window=9m&as_of=latest", "/api/securities/NTRA/chart?frequency=weekly&window=5y&as_of=latest" ], "route_registry_route": "../../assets/security-page-routes.js#NTRA", "chart_level_registry_route": "../../assets/chart-level-rules.js#NTRA", "fallback_chart_route": "../index.html?ticker=NTRA", "source_refs_projected": [ "SRC_SEC_Q1_2026_10Q", "SRC_SEC_10K_2025", "SRC_SEC_10K_2024", "SRC_COMP_Q1_2026_RELEASE", "SRC_COMP_FY2025_RELEASE", "SRC_COMP_Q1_2025_RELEASE", "SRC_COMP_Q2_2025_RELEASE", "SRC_COMP_Q3_2025_RELEASE", "SRC_COMP_ASCO_2026_RELEASE", "SRC_PROXY_2026", "SRC_COMP_FORESIGHT_8K", "SRC_LOCAL_DAILY_OHLC", "SRC_LOCAL_SHORT_INTEREST", "SRC_LOCAL_INSIDER_TRANSACTIONS" ] }, "web_source_trail": { "checked_at": "2026-06-24", "official_links": [ { "label": "Natera investor relations overview", "url": "https://investor.natera.com/overview/default.aspx", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "dated_note": "IR overview checked 2026-06-24; page describes Natera as focused on cfDNA testing across women's health, oncology, and organ health and lists more than 400 peer-reviewed publications." }, { "label": "Natera IR analyst coverage", "url": "https://investor.natera.com/stock-info/analyst-coverage/default.aspx", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "dated_note": "Checked 2026-06-24; page listed 16 analyst firms and states analyst opinions do not represent Natera or management." }, { "label": "Natera IR SEC filings", "url": "https://investor.natera.com/financials/sec-filings/default.aspx", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "dated_note": "Checked 2026-06-24; the company-hosted filings route loaded, though filing rows render dynamically." }, { "label": "Natera events and presentations", "url": "https://investor.natera.com/events-and-presentations/default.aspx", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "dated_note": "Checked 2026-06-24; page provides official events and presentations route, with archive rows requiring browser rendering." }, { "label": "SEC company browse", "url": "https://www.sec.gov/edgar/browse/?CIK=1604821&owner=exclude", "publication_date_or_period": "CIK 1604821", "checked_at": "2026-06-24", "dated_note": "SEC filing discovery route for Natera, CIK 1604821." }, { "label": "Q1 2026 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000162828026032478/ntra-20260331.htm", "publication_date_or_period": "quarter ended 2026-03-31", "checked_at": "2026-06-24", "dated_note": "Quarterly report for the period ended 2026-03-31; used for product revenue, cash, debt, share count, Foresight, Medicare, and legal/regulatory context." }, { "label": "FY2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm", "publication_date_or_period": "year ended 2025-12-31", "checked_at": "2026-06-24", "dated_note": "Annual report for the year ended 2025-12-31; used for reimbursement and legal/regulatory risk routing." }, { "label": "2026 DEF 14A", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926047770/ntra-20260611xdef14a.htm", "publication_date_or_period": "2026 proxy", "checked_at": "2026-06-24", "dated_note": "Proxy route for insider/director ownership and governance context." }, { "label": "Natera Q1 2026 earnings release", "url": "https://natera.com/company/news/natera-reports-first-quarter-2026-financial-results", "publication_date_or_period": "Q1 2026 results", "checked_at": "2026-06-24", "dated_note": "Official release route carried in the filed source trail; used for Q1 revenue, tests, oncology volume, gross margin, cash inflow, and FY2026 guidance." }, { "label": "Natera ASCO 2026 release", "url": "https://natera.com/company/news/natera-to-present-35-studies-at-asco-extending-clinical-data-leadership-in-oncology", "publication_date_or_period": "ASCO 2026", "checked_at": "2026-06-24", "dated_note": "Official release route carried in the filed source trail; used for the 35-study oncology evidence program and more than 400-publication context." }, { "label": "Foresight 8-K exhibit", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/tm2532406d4_ex99-1.htm", "publication_date_or_period": "2025 acquisition exhibit", "checked_at": "2026-06-24", "dated_note": "SEC exhibit route for the Foresight acquisition announcement and MRD technology description." } ], "street_view_items": [ { "provider": "StockAnalysis", "url": "https://stockanalysis.com/stocks/ntra/forecast/", "publication_date_or_period": "last checked by provider 2026-06-23", "checked_at": "2026-06-24", "detail": "Page showed 21 analysts polled by S&P Global, Buy consensus, average target $259.05, low $193, high $300, and latest listed actions from Canaccord, Piper Sandler, BTIG, Leerink, and RBC." }, { "provider": "MarketBeat", "url": "https://www.marketbeat.com/stocks/NASDAQ/NTRA/forecast/", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "detail": "Page showed 21 Wall Street analyst ratings, Moderate Buy consensus, average target $257.71, high $300, and low $172." }, { "provider": "Natera investor relations", "url": "https://investor.natera.com/stock-info/analyst-coverage/default.aspx", "publication_date_or_period": "checked route", "checked_at": "2026-06-24", "detail": "Natera lists covering firms but does not provide rating, target, or consensus data on the official coverage page." } ] }, "chart": { "ticker": "NTRA", "initializer": "assets/report.js initializeSecurityChartPage reads data-security-ticker=\"NTRA\"", "api_required": true, "daily_endpoint": "/api/securities/NTRA/chart?frequency=daily&window=9m&as_of=latest", "weekly_endpoint": "/api/securities/NTRA/chart?frequency=weekly&window=5y&as_of=latest", "price_source": "Local report API backed by discovery daily_ohlc and derived weekly rows.", "instrument_source": "Local report API backed by discovery instruments.", "chart_level_registry_route": "../../assets/chart-level-rules.js#NTRA", "route_registry_route": "../../assets/security-page-routes.js#NTRA", "fallback_route": "../index.html?ticker=NTRA" }, "page_sections": [ { "id": "selected-security", "title": "Selected-Security Chart", "role": "Live local API chart host and chart-rule attachment point." }, { "id": "current-company-view", "title": "Current Company Proof Window", "role": "Setup, measured base, proof issue, valuation context, and next evidence in the console proof block." }, { "id": "business-profile-exposure", "title": "Business Profile, Segments, And Exposure Map", "role": "Business model, single-segment disclosure limits, oncology, women's health, reimbursement, and Foresight exposure cards." }, { "id": "relative-value-drivers", "title": "Relative Value And Value Driver Board", "role": "Oncology growth, ASP and reimbursement, gross margin conversion, cash quality, and per-share discipline." }, { "id": "guidance-path", "title": "Guidance Path And Tests", "role": "FY2026 guide raise, Q2 validation burden, reimbursement tests, and margin-to-cash checks." }, { "id": "operating-evidence-kpis", "title": "Operating Evidence And KPIs", "role": "Dashboard metric strips and compact source-routed KPI evidence." }, { "id": "financial-quality-capital-allocation", "title": "Financial Quality And Capital Ledger", "role": "Liquidity, OCF, capex, AR quality, Foresight consideration, contingent consideration, and dilution." }, { "id": "competitive-position", "title": "Competitive Position", "role": "Oncology evidence engine, commercial scale, balance-sheet capacity, and unproven reimbursement/product-line economics." }, { "id": "ownership-flows-valuation-street", "title": "Ownership, Flows, Valuation, And Street View", "role": "Official coverage list, aggregator consensus, recent rating actions, valuation multiple, short interest, and insider flow." }, { "id": "scenario-assessment", "title": "Scenario Assessment And Sensitivities", "role": "Base, upside, and downside paths from the profile projection." }, { "id": "monitoring-triggers", "title": "Monitoring Trigger Stack", "role": "Business-evidence checks for Q2, reimbursement, cash quality, operating spend, and Foresight." }, { "id": "risks-invalidations-quality-flags", "title": "Risks, Invalidations, And Quality Punch Cards", "role": "Reimbursement, operating leverage, valuation, legal/regulatory, Foresight, and disclosure-opacity flags." }, { "id": "diagnostics-freshness-unknowns", "title": "Diagnostics, Freshness, And Known Unknowns", "role": "Source freshness, stale-source status, diagnostics, segment-economics gaps, transcript/deck gaps, Foresight unknowns, and 13F limits." }, { "id": "links-filings", "title": "Links, Filings, And Source Bay", "role": "Human-useful links to canonical lane, raw projections, investor relations, SEC filings, latest filings, official releases, aggregator routes, metadata, and local chart endpoints." } ], "machine_provenance_limitations": [ "Report JSON is a manual report-layer projection, not a canonical research refresh.", "Live chart values depend on the local report API and are not persisted in report.json.", "Chart overlays belong in assets/chart-level-rules.js; report JSON stores only the registry route.", "The latest profile reused upstream inputs, so the page preserves upstream hashes and does not imply fresh independent collection.", "Market-data-provider short interest, insider transactions, valuation multiple, and price behavior are as of the latest lane snapshot and may differ from live market data.", "Transcript coverage, investor-deck parsing, 13F holdings, product-line economics, and Foresight standalone contribution remain unresolved source gaps.", "Street-view items are sourced from public aggregator pages and official analyst-coverage lists; they should be refreshed before being used as current consensus evidence." ], "revision": { "version": 1, "created_at": "2026-06-24", "updated_at": "2026-06-24T04:52:11Z", "updated_label": "Created NTRA detailed security page.", "metadata_path": "securities/ntra/report.json", "curation_source": "Manual report projection from ../../../knowledge/wiki/lanes/security/ntra.md plus official Natera IR/SEC links and dated street-view aggregator checks.", "change_note": "Added the NTRA detailed security page using the shared security-article-page shape, selected-security chart API hooks, source routes, trade-plan host, route registry contract, and chart-overlay boundary." } }